CD4 and COVID-19: JAK/STAT is also implicated in the aberrant immune response in SARS-CoV-2-infected respiratory epithelial cells with the activation of CD4+ and CD8+ positive T cells, NK cells, monocytes and the release of high levels of pro-inflammatory cytokines, representing an attractive target in COVID-19 patients.